Last updated: February 20, 2026
This report provides a comprehensive overview of the market landscape and pricing outlook for the drug identified by NDC 70000-0187.
Product Overview
NDC 70000-0187 corresponds to Keytruda (pembrolizumab), a monoclonal antibody developed by Merck used in oncology treatments. Approved indications include melanoma, non-small cell lung carcinoma, head and neck squamous cell carcinoma, among others.
Market Landscape
Market Size and Growth
- The global immuno-oncology market was valued at approximately USD 13.3 billion in 2022.
- Compound annual growth rate (CAGR) is projected at 11.2% from 2023 to 2030.
- Keytruda occupies over 65% of the U.S. market share within its primary indications.
Competitive Position
- Major competitors include Bristol-Myers Squibb’s Opdivo (nivolumab) and AstraZeneca’s Imfinzi (durvalumab).
- In 2022, Keytruda generated USD 13.6 billion in worldwide sales, representing 30% of Merck’s total revenue.
- Regulatory trends favor approval of expanding indications, extending product lifecycle.
Market Drivers and Barriers
- Drivers include increasing incidence of cancers eligible for pembrolizumab, approvals for new indications, and ongoing combination therapy trials.
- Barriers include high drug costs, reimbursement challenges, and emerging biosimilar competition in select markets.
Pricing Trends and Projections
Current Pricing
- List price per dose in the U.S.: approximately USD 13,000 (based on a 200 mg dose).
- Average annual treatment cost: USD 150,000 to USD 170,000 per patient, depending on dosage and duration.
- Wholesale acquisition cost (WAC) remains stable; prices in other markets, such as Europe, are approximately 20% lower due to negotiated discounts.
Future Price Dynamics
- Price erosion in mature markets expected to be limited due to patent protection extending until at least 2028.
- Price reductions are anticipated mainly through managed care negotiations, value-based agreements, and biosimilar competition in non-U.S. markets.
- In emerging markets, prices are projected to remain significantly lower—potentially 50% less than U.S. prices—to improve access.
Impact of Patent Expiry and Biosimilars
- Patent protection in key territories expires around 2028.
- Biosimilar versions are expected to enter markets shortly thereafter, possibly reducing prices by 20-30%.
- Merck has initiated litigation to delay biosimilar entry in some regions.
Regulatory and Policy Influence
- Proposed regulations around value-based care could influence reimbursement rates and net prices.
- Changes in national healthcare policies, such as U.S. Medicare pricing reforms, could affect revenue streams and pricing strategies.
Investment and R&D Outlook
- Merck continues clinical trials for new indications and combination therapies.
- Significant investment in expanding the drug’s label and geographic footprint sustains long-term revenue potential.
- Partnerships and licensing agreements are anticipated to enhance market penetration and access in underrepresented regions.
Key Takeaways
- NDC 70000-0187 (Keytruda) holds a dominant position in the immuno-oncology market.
- Sales are driven by approved indications, expanding labels, and clinical trial pipeline.
- Pricing remains high in developed markets with stability until patent expiry.
- Biosimilar entry post-2028 could lead to substantial price reductions.
- Market growth forecasted at over 11% CAGR through 2030, driven by increased cancer prevalence and expanded indications.
FAQs
1. When is patent expiry for Keytruda?
Patent protections in major markets, including the U.S. and Europe, are expected to expire around 2028.
2. How will biosimilar competition impact prices?
Biosimilar entry could reduce list prices by 20-30%, but actual price declines depend on regional negotiations and market access strategies.
3. What are the primary indications for NDC 70000-0187?
Keytruda is approved for melanoma, non-small cell lung cancer, head and neck cancers, Hodgkin lymphoma, and several other tumors.
4. How does the pricing in emerging markets compare to developed markets?
Prices in emerging markets are generally 50% or more lower, driven by negotiated discounts and affordability strategies.
5. What regulatory trends could influence future prices?
Policies favoring value-based pricing and transparency are likely to impact reimbursement rates and net prices globally.
References
[1] IQVIA. (2022). The Global Oncology Market.
[2] Merck & Co. Annual Reports. (2022).
[3] Evaluate Pharma. (2023). World Preview 2023: Outlook to 2028.
[4] U.S. Food and Drug Administration. (2022). Approved Label for Keytruda.
[5] BioCentury. (2023). Biosimilar Outlook for Oncology Drugs.
